Profusa, Inc. PFSA

Profusa received a positive decision from GMED on ISO 13485 certification, expected in early October, while additional European MDR conformity assessment work remains before the Lumee Oxygen Platform can receive a CE mark. Key Investor TakeawaysProfusa (NASDAQ:PFSA) received a positive decision from notified body GMED regarding certification of its quality management system to ISO 13485.

Berkeley, CA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced today that on September 9, 2026, the Company received a letter (the “Compliance Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has demonstrated compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”). The Company remains subject to a one-year Mandatory Panel Monitor (the “Monito

Berkeley, CA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced that it has received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that on August 14, 2026, following the effectiveness of the Company’s 1-for-4 reverse stock split, the Company had less than the 500,000 publicly held shares required under Nasdaq Listing Rule 5550(a)(4) (the “Rule”). The Notice further stated that based on t

Profusa (NASDAQ:PFSA) reported progress toward satisfying conditions tied to its potential G3 Vision Labs acquisition, while second-quarter 2026 results showed a widening net loss and limited cash resources. The company is pursuing debt-to-equity exchanges and other balance-sheet changes as it works toward potentially exercising its option to acquire the commercial-stage diagnostics business.

Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of which $4.57 million was converted into Series A Convertible Preferred Stock Sufficient working capital obtained to fund operations for near term PCAOB audited 2024 and 2025 financials of G3 and Subsidiaries are expected by mid-September Reverse stock split successfully executed August 20, 2026 BERKELEY, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health c

BERKELEY, California, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-four (1:4) reverse stock split of its common stock. The

If the acquisition goes ahead, Profusa will add several routine chemistry, toxicology and pathology diagnostic offerings to its portfolio.

BERKELEY, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of an Option Agreement (the “Agreement”) which provides Profusa the right and option, but not the obligation, subject to satisfaction of the conditions described below, to acquire G3 Vision Labs, Inc. (“G3”) and its subsidiaries, Med Screen Laboratories Inc., Dominion Diagnostics LLC and Acutis Diagnostics Inc. G3's 2

Profusa (NASDAQ:PFSA) has signed a non-binding term sheet to acquire a commercial-stage diagnostics company with estimated 2025 net revenue of approximately $111 million, while also reshaping its executive leadership as it pivots toward a diagnostics-focused business model. Key Investor TakeawaysProfusa (NASDAQ:PFSA) signed a non-binding term sheet to acquire a commercial-stage diagnostics company.